“Real world survey” of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients

Abstract

Advanced cancer treatment is a huge challenge and new ideas and strategies are required. Hydrogen exerts antioxidant and anti-inflammatory effects that may be exploited to control cancer, the occurrence and progression of which is closely related to peroxidation and inflammation. We conducted a prospective follow-up study of 82 patients with stage III and IV cancer treated with hydrogen inhalation using the "real world evidence" method. After 3-46 months of follow-up, 12 patients died in stage IV. After 4 weeks of hydrogen inhalation, patients reported significant improvements in fatigue, insomnia, anorexia and pain. Furthermore, 41.5% of patients had improved physical status, with the best effect achieved in lung cancer patients and the poorest in patients with pancreatic and gynecologic cancers. Of the 58 cases with one or more abnormal tumor markers elevated, the markers were decreased at 13-45 days (median 23 days) after hydrogen inhalation in 36.2%. The greatest marker decrease was in achieved lung cancer and the lowest in pancreatic and hepatic malignancies. Of the 80 cases with tumors visible in imaging, the total disease control rate was 57.5%, with complete and partial remission appearing at 21-80 days (median 55 days) after hydrogen inhalation. The disease control rate was significantly higher in stage III patients than in stage IV patients (83.0% and 47.7%, respectively), with the lowest disease control rate in pancreatic cancer patients. No hematological toxicity was observed although minor adverse reactions that resolved spontaneously were seen in individual cases. In patients with advanced cancer, inhaled hydrogen can improve patients' quality-of-life and control cancer progression. Hydrogen inhalation is a simple, low-cost treatment with few adverse reactions that warrants further investigation as a strategy for clinical rehabilitation of patients with advanced cancer. The study protocol received ethical approval from the Ethics Committee of

A narrative review of hydrogen oncology: from real world survey to real world evidence

“…We have conducted a voluntary field survey in patients diagnosed with cancer who inhaled hydrogen at home or at rehabilitation centers from 2014 to 2019. 2 Follow-up was performed on 82 patients with advanced (stage III and IV) cancer. The patients used the Hydrogen-oxygen Atomizer (AMS-H-03, Shanghai Asclepius Meditec Co., Ltd., Shanghai, China), which provided 66.7% hydrogen with mixed 33.3% oxygen with gas flow at 3000 mL/min.…”

“…Subsequently, it was discovered that the patient's improvements and recovery were due to the large amount of hydrogen gas contained in the holy water. Since a real world survey of 82 patients with advanced cancer from China was reported, 2 “hydrogen oncology” obtained the real world evidence for the first time. The articles used in this oncology review were retrieved by replicating the search terms of Chen et al 2 An electronic search of the Medline database for literature describing clinical hydrogen therapy for cancer patients from 2000 to 2019.…”

“…Since a real world survey of 82 patients with advanced cancer from China was reported, 2 “hydrogen oncology” obtained the real world evidence for the first time. The articles used in this oncology review were retrieved by replicating the search terms of Chen et al 2 An electronic search of the Medline database for literature describing clinical hydrogen therapy for cancer patients from 2000 to 2019. The results were further screened by title and abstract to only cancer treatment, not Complications treatment.…”

A narrative review of hydrogen-oxygen mixture for medical purpose and the inhaler thereof

“…With the support of hydrogen inhaler AMS-H-01/AMS-H-03 provided by Asclepius Meditec Co., Ltd., tens of animal studies or pilot clinical trials based on inhaled gas which combines H 2 (concentration of ~66%) with O 2 (concentration of ~34%) were accomplished and published. 14 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 Additionally, recent formal clinic trials based on the same inhaler AMS-H-01/AMS-H-03 also revealed positive results in respiratory diseases, such as allergic rhinitis, asthma, chronic obstructive pulmonary disease, etc. Especially, it is recommended to use the mixed gas of 66.6% H 2 /33.3% O 2 for treating coronavirus disease-19 (COVID-19) patients as described in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia, 7 Edition released by National Health Commission of China, 55 and such guideline is also republished in English by the World Health Organization China Office.…”

“…56 Moreover, a survey report regarding 82 cancer patients with the help of the same inhaler AMS-H-01 also demonstrated that in patients with advanced cancer, inhaling gas with H 2 concentration of 64–67% can improve patients’ quality of life and control cancer progression. 53 Therefore, how to provide safe and durable hydrogen-oxygen inhalers with higher H 2 concentration is key factor to expedite and realize the hydrogen biomedicine. Search strategy is shown in .…”